等待開盤 10-08 09:30:00 美东时间
+0.120
+0.09%
Two Democratic lawmakers are said to have called for independent probes into taxpayer-funded TV ads featuring President Donald Trump running ahead of the November midterm elections. Representative Jam...
10-01 17:41
FTI Consulting appoints James Bulloss, Kasey Lin, Theo Kitsanelis, and Matthew Mansell-Ahmed as Managing Directors in its UK Corporate Finance segment, enhancing its Turnaround & Restructuring capabilities. The appointments strengthen the firm's ability to assist clients facing financial distress, liquidity challenges, and complex transactions across the UK. Each new director brings specialized expertise in areas such as restructuring, distressed...
10-01 08:00
FTI Consulting appoints Eileen Fargis as Senior Managing Director in its Power, Renewables & Energy Transition practice. With over 30 years of experience in power, energy, and infrastructure, Fargis will advise clients on growth, capital allocation, performance improvement, and restructuring. Her expertise spans strategic, financial, and operational matters, including transaction advisory and financial turnarounds. Fargis has held senior roles in...
09-22 11:30
Diversified Energy Company announced on May 6, 2026, a Q1 2026 Dividend of 29 cents per share, payable on September 30, 2026, to shareholders registered on August 28, 2026. Shareholders opting for GBP payments will receive 21.396 pence per share, based on the September 10, 2026 exchange rate of GBP 0.73781 = US $1.00. For more information, contact Doug Kris at Diversified Energy Company or FTI Consulting.
09-17 06:00
EyePoint, Inc. granted non-statutory stock options to a new employee outside its 2023 Long-Term Incentive Plan, totaling 3,000 shares, under NASDAQ Listing Rule 5635(c)(4). The options, exercisable at $3.66 per share, vest over four years with 25% on the first anniversary and the remainder in monthly installments. EyePoint, a biopharmaceutical company, is developing DURAVYU™, an investigational treatment for retinal diseases, currently in Phase 3...
09-16 11:00
Diversified Energy Company announced a Q1 2026 dividend of 29 cents per share, payable on September 30, 2026, to shareholders registered as of August 28, 2026. Shareholders opting for GBP payments will receive 21.567 pence per share, based on the September 10, 2026 exchange rate of GBP 0.73781 = US $1.00. The company focuses on acquiring and optimizing energy assets sustainably, generating reliable cash flow and shareholder value.
09-16 06:00
Senseonics and Beta Bionics collaborate to integrate Eversense 365 CGM with iLet Bionic Pancreas for enhanced diabetes management. The combined system aims to simplify insulin delivery and glucose monitoring, offering a year-long sensing solution without carb counting. Commercial launch planned for Q4 2026.
09-14 11:00
Diversified Energy Company announced the acquisition of Birch Permian Holdings, Inc. for $1.8 billion, expanding its Permian Basin operations and increasing production by ~35% and Adjusted EBITDA by ~55%. The deal enhances Diversified's position as a premier Permian operator, with Birch's high-quality, low-decline assets and integrated infrastructure. Carlyle will support the transaction through an $1.5 billion ABS, and the partnership will expan...
09-02 23:26
EyePoint, Inc. will participate in several upcoming conferences, including the Citi 2026 Biopharma Back to School Conference on September 9, 2026, the Cantor Global Healthcare Conference 2026 on September 10, 2026, and the Morgan Stanley Global Healthcare Conference on September 15, 2026. Fireside chats from these events will be available on the Company’s website. Additionally, EyePoint will present at The Retina Society 59th Annual Scientific Me...
09-02 11:00
Skye Bioscience and Redx Pharma have entered into a definitive transaction agreement to merge, forming Fibrx Therapeutics, a fibrosis-focused company. The combined entity will trade on Nasdaq and is backed by $125 million in financing, aiming to fund operations through 2029. Fibrx’s lead program, RXC008, a GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn’s disease, is set to begin a Phase 2 clinical trial with topline data expected in H2 ...
08-14 13:33